JP2005527209A - 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター - Google Patents
疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター Download PDFInfo
- Publication number
- JP2005527209A JP2005527209A JP2003586177A JP2003586177A JP2005527209A JP 2005527209 A JP2005527209 A JP 2005527209A JP 2003586177 A JP2003586177 A JP 2003586177A JP 2003586177 A JP2003586177 A JP 2003586177A JP 2005527209 A JP2005527209 A JP 2005527209A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- pain
- seq
- domain
- γpkc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 233
- 208000002193 Pain Diseases 0.000 title claims abstract description 148
- 230000036407 pain Effects 0.000 title claims abstract description 134
- 239000003112 inhibitor Substances 0.000 title description 9
- 102100037314 Protein kinase C gamma type Human genes 0.000 title description 5
- 108010062154 protein kinase C gamma Proteins 0.000 title 1
- 108090000315 Protein Kinase C Proteins 0.000 claims abstract description 59
- 102000003923 Protein Kinase C Human genes 0.000 claims abstract description 54
- 108010044467 Isoenzymes Proteins 0.000 claims abstract description 53
- 230000000694 effects Effects 0.000 claims abstract description 53
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 6
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 6
- 238000012360 testing method Methods 0.000 claims description 49
- 238000007726 management method Methods 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 15
- 230000008058 pain sensation Effects 0.000 claims description 14
- 208000000094 Chronic Pain Diseases 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 208000005298 acute pain Diseases 0.000 claims description 3
- 238000012875 competitive assay Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 150000002894 organic compounds Chemical class 0.000 claims description 3
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 40
- 230000036592 analgesia Effects 0.000 abstract description 7
- 230000003278 mimic effect Effects 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 230000014725 late viral mRNA transcription Effects 0.000 abstract description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 58
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 42
- 241000700159 Rattus Species 0.000 description 30
- 229960002504 capsaicin Drugs 0.000 description 21
- 235000017663 capsaicin Nutrition 0.000 description 21
- 238000011282 treatment Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 210000002683 foot Anatomy 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 208000004454 Hyperalgesia Diseases 0.000 description 12
- 102000006438 Receptors for Activated C Kinase Human genes 0.000 description 12
- 108010044157 Receptors for Activated C Kinase Proteins 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000006399 behavior Effects 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 208000035154 Hyperesthesia Diseases 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000005945 translocation Effects 0.000 description 7
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 101001026864 Homo sapiens Protein kinase C gamma type Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229910003460 diamond Inorganic materials 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 108010085520 epsilonV1-2 peptide Proteins 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000000929 nociceptor Anatomy 0.000 description 4
- 108091008700 nociceptors Proteins 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000004550 Postoperative Pain Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 206010053552 allodynia Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000020341 sensory perception of pain Effects 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010064012 Central pain syndrome Diseases 0.000 description 2
- 108700006830 Drosophila Antp Proteins 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 102000042846 PKC family Human genes 0.000 description 2
- 108091082203 PKC family Proteins 0.000 description 2
- 210000003766 afferent neuron Anatomy 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 230000000917 hyperalgesic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 230000008052 pain pathway Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 230000026416 response to pain Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- HXQRGYNEDCHJPJ-UHFFFAOYSA-N 2,6-diamino-n-[(1-tridecanoylpiperidin-2-yl)methyl]hexanamide Chemical compound CCCCCCCCCCCCC(=O)N1CCCCC1CNC(=O)C(N)CCCCN HXQRGYNEDCHJPJ-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 235000004391 Chenopodium capitatum Nutrition 0.000 description 1
- 244000038022 Chenopodium capitatum Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010078137 Protein Kinase C-epsilon Proteins 0.000 description 1
- 102000014458 Protein Kinase C-epsilon Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000003070 anti-hyperalgesia Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006406 biphasic response Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229930194791 calphostin Natural products 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000054 fungal extract Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000021646 inflammation of heart layer Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108010050991 protein kinase C zeta Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000031893 sensory processing Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37453002P | 2002-04-22 | 2002-04-22 | |
| PCT/US2003/012542 WO2003089457A2 (en) | 2002-04-22 | 2003-04-22 | Peptide inhibitors of protein kinase c ϝ for pain management |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009010402A Division JP2009091372A (ja) | 2002-04-22 | 2009-01-20 | 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2005527209A true JP2005527209A (ja) | 2005-09-15 |
Family
ID=29251202
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003586177A Pending JP2005527209A (ja) | 2002-04-22 | 2003-04-22 | 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター |
| JP2003586176A Withdrawn JP2005523326A (ja) | 2002-04-22 | 2003-04-22 | プロテインキナーゼｃのペプチドインヒビター |
| JP2009010402A Pending JP2009091372A (ja) | 2002-04-22 | 2009-01-20 | 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター |
| JP2009011456A Pending JP2009102392A (ja) | 2002-04-22 | 2009-01-21 | プロテインキナーゼｃのペプチドインヒビター |
| JP2012128849A Pending JP2012176978A (ja) | 2002-04-22 | 2012-06-06 | プロテインキナーゼｃのペプチドインヒビター |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003586176A Withdrawn JP2005523326A (ja) | 2002-04-22 | 2003-04-22 | プロテインキナーゼｃのペプチドインヒビター |
| JP2009010402A Pending JP2009091372A (ja) | 2002-04-22 | 2009-01-20 | 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター |
| JP2009011456A Pending JP2009102392A (ja) | 2002-04-22 | 2009-01-21 | プロテインキナーゼｃのペプチドインヒビター |
| JP2012128849A Pending JP2012176978A (ja) | 2002-04-22 | 2012-06-06 | プロテインキナーゼｃのペプチドインヒビター |
Country Status (6)
| Country | Link |
|---|---|
| US (8) | US7507711B2 (enExample) |
| EP (3) | EP2332559A1 (enExample) |
| JP (5) | JP2005527209A (enExample) |
| AU (4) | AU2003234186B2 (enExample) |
| CA (3) | CA2481512C (enExample) |
| WO (2) | WO2003089456A2 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006525948A (ja) * | 2003-05-16 | 2006-11-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 離脱症状における使用のためのプロテインキナーゼｃペプチド |
| JP2010516709A (ja) * | 2007-01-19 | 2010-05-20 | カイ ファーマシューティカルズ インコーポレーティッド | 疼痛減弱のためのイプシロン阻害化合物の使用方法 |
| JP2010516707A (ja) * | 2007-01-19 | 2010-05-20 | カイ ファーマシューティカルズ インコーポレーティッド | ペプチド組成物の安定性および送達効率を上昇させるための修飾方法 |
| JP2010523598A (ja) * | 2007-04-06 | 2010-07-15 | カイ・ファーマシューティカルズ・インコーポレイテッド | 痛みの軽減のためのガンマ阻害剤化合物の使用方法 |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003089456A2 (en) * | 2002-04-22 | 2003-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide inhibitors of protein kinase c |
| US6933275B2 (en) * | 2002-05-01 | 2005-08-23 | The Board Of Trustees Of The Leland Stanford Junior University | Protein kinase C peptides for use in withdrawal |
| WO2004084889A1 (en) * | 2003-03-28 | 2004-10-07 | Pfizer Inc. | Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons |
| WO2005032575A1 (en) * | 2003-10-02 | 2005-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Protein kinase c peptides for use in withdrawal |
| CA2543257C (en) | 2003-10-24 | 2013-12-31 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
| US8507277B2 (en) * | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
| US20090208478A1 (en) * | 2003-10-24 | 2009-08-20 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| CA2549052A1 (en) * | 2003-12-11 | 2005-06-30 | The Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific antagonists of protein kinase c |
| US7265092B2 (en) * | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| US20060148700A1 (en) * | 2004-11-10 | 2006-07-06 | Daria Mochly-Rosen | Methods and compositions for reducing injury to a transplanted organ |
| US20060160062A1 (en) * | 2005-01-14 | 2006-07-20 | Young Lindon H | Perfusion and/or preservation solution for organs |
| WO2006108270A1 (en) * | 2005-04-11 | 2006-10-19 | Pharmagap Inc. | Inhibitors of protein kinases and uses thereof |
| US20100041597A1 (en) * | 2005-08-05 | 2010-02-18 | Jenny Phipps | Peptides targeted to protein kinase c isoforms and uses thereof |
| CA2620364A1 (en) | 2005-08-26 | 2007-03-01 | David C. Yeomans | Methods for treatment of headaches by administration of oxytocin |
| JP5269596B2 (ja) * | 2005-09-19 | 2013-08-21 | カイ ファーマシューティカルズ インコーポレーティッド | 血管新生のプロテインキナーゼｃペプチドモジュレーター |
| JP2009531335A (ja) * | 2006-03-30 | 2009-09-03 | サルペップ バイオテクノロジー インコーポレイテッド | 神経障害性疼痛の抑制および治療 |
| WO2007143119A2 (en) * | 2006-06-01 | 2007-12-13 | The Board Of Trustees Of The Leland Stanford Junior University | Method of preventing progression of hypertension-induced heart failure with pkc peptides |
| US20090062208A1 (en) * | 2007-02-06 | 2009-03-05 | Mochly-Rosen Daria D | Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor |
| WO2008154004A2 (en) * | 2007-06-07 | 2008-12-18 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of tumor metastases using protein kinase c (pkc) inhibitors |
| WO2009085270A2 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions |
| US20090318351A1 (en) * | 2008-03-12 | 2009-12-24 | Kevin Grimes | Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist |
| MX2010010569A (es) * | 2008-03-27 | 2010-11-04 | Nestec Sa | Metodos para incrementar la absorcion de peptidos, peptidomimeticos y otros sustratos de proteina de transporte gastrointestinal. |
| WO2010019965A1 (en) * | 2008-08-15 | 2010-02-18 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection |
| JP6189581B2 (ja) | 2009-02-20 | 2017-08-30 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 幹細胞の分化のための方法および組成物 |
| US8372642B2 (en) * | 2009-02-27 | 2013-02-12 | Cellular Dynamics International, Inc. | Differentiation of pluripotent cells |
| CA2754482A1 (en) * | 2009-03-06 | 2010-09-10 | Angstrom Pharmaceuticals, Inc. | Compositions and methods for modulation of cell migration |
| WO2010111533A2 (en) * | 2009-03-25 | 2010-09-30 | Kai Pharmaceuticals, Inc. | Transdermal delivery of pkc modulatory peptides through microporated skin |
| EP2942060A1 (en) | 2009-09-29 | 2015-11-11 | Joslin Diabetes Center, Inc. | Use of Protein Kinase C Delta (PKCD) Inhibitors to Treat Diabetes, Obesity and, Hepatic Steatosis |
| AU2011223563A1 (en) * | 2010-03-05 | 2012-11-01 | Angstrom Pharmaceuticals, Inc. | Modulation of intracellular signaling |
| US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
| JP6061932B2 (ja) | 2011-08-12 | 2017-01-18 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ピルビン酸デヒドロゲナーゼキナーゼを特異的にレギュレートするための組成物および方法 |
| EP2841563B1 (en) | 2012-04-24 | 2019-06-12 | Dan S. Kaufman | Method for developing natural killer cells from stem cells |
| CA2923765C (en) | 2013-09-18 | 2021-06-29 | University Of Canberra | Stem cell modulation ii |
| WO2016003450A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Pkc-epsilon inhibitors |
| AU2015309686B2 (en) | 2014-08-25 | 2020-05-14 | Epiaxis Therapeutics Pty Ltd | Compositions for modulating cancer stem cells and uses therefor |
| HRP20231438T1 (hr) | 2015-01-07 | 2024-06-07 | Tonix Pharma Limited | Formulacije oksitocina koje sadrže magnezij i načini uporabe |
| MX2018012351A (es) | 2016-04-12 | 2019-02-07 | Trigemina Inc | Formulaciones de oxitocina que contienen magnesio y metodos de uso. |
| US12410143B2 (en) | 2017-01-17 | 2025-09-09 | Michael David FORREST | Therapeutic inhibitors of the reverse mode of ATP synthase |
| BR112019028172A2 (pt) | 2017-07-13 | 2020-10-06 | Michael David Forrest | moduladores terapêuticos do modo reverso da atp sintase |
| JP2021502405A (ja) | 2017-11-08 | 2021-01-28 | エピアクシス セラピューティクス プロプライエタリー リミテッド | 免疫原性組成物及びその使用 |
| EP4078221A1 (en) * | 2019-12-16 | 2022-10-26 | Sony Semiconductor Solutions Corporation | Time-of-flight imaging circuitry, time-of-flight imaging system, time-of-flight imaging method |
| US20230104831A1 (en) * | 2020-03-31 | 2023-04-06 | Toray Industries, Inc. | An image analysis device, a control method for an image analysis device, an image analysis system, and a control method for an image analysis system |
| WO2022157548A1 (en) | 2021-01-24 | 2022-07-28 | Forrest Michael David | Inhibitors of atp synthase - cosmetic and therapeutic uses |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000004914A1 (en) * | 1998-07-21 | 2000-02-03 | Cytovia, Inc. | Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof |
| JP2005523326A (ja) * | 2002-04-22 | 2005-08-04 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | プロテインキナーゼｃのペプチドインヒビター |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4351829A (en) | 1980-09-26 | 1982-09-28 | Farmitalia Carlo Erba Spa | Use of polypeptides as analgesic drugs |
| DE69321962T2 (de) | 1992-08-21 | 1999-07-01 | Biogen Inc | Von tat abgeleitete transportpolypeptide |
| US5776685A (en) * | 1993-07-19 | 1998-07-07 | Joslin Diabetes Center | Protein kinase C assay |
| US5935803A (en) | 1994-02-01 | 1999-08-10 | Terrapin Technologies, Inc. | Methods to identify immunomodulators using cognate interaction of PKC-theta |
| US5783405A (en) | 1994-02-01 | 1998-07-21 | Terrapin Technologies, Inc. | Rapid screening method for effectors of signal transduction |
| US6165977A (en) | 1996-10-18 | 2000-12-26 | Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific activators of protein kinase C methods and compositions |
| US6376476B1 (en) * | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
| US6218113B1 (en) * | 1998-02-24 | 2001-04-17 | Incyte Genomics, Inc. | Human protein kinase C inhibitor |
| CA2336709A1 (en) | 1998-07-06 | 2000-01-13 | Robert O. Messing | Use of inhibitors of protein kinase c epsilon to treat pain |
| US6376467B1 (en) * | 1998-10-09 | 2002-04-23 | The Regents Of The University Of California | Use of inhibitors of protein kinase C epsilon to treat pain |
| CN1313895A (zh) * | 1998-09-14 | 2001-09-19 | 泛太平洋制药公司 | 蜂毒蛋白的有用特性和编码这种蜂毒蛋白的基因 |
| EP1115847A1 (en) * | 1998-09-25 | 2001-07-18 | Children's Medical Center Corporation | Short peptides which selectively modulate the activity of protein kinases |
| GB9905218D0 (en) * | 1999-03-09 | 1999-04-28 | Univ Glasgow | Neurodegenerative disorder related gene |
| JP2003516760A (ja) * | 1999-12-02 | 2003-05-20 | ユニヴァーシティー オブ ダンディー | プロテインキナーゼ調節 |
| CN1300845A (zh) * | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽－人二酰基甘油蛋白激酶亚单位9和编码这种多肽的多核苷酸 |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US6496425B1 (en) * | 2000-08-21 | 2002-12-17 | Micron Technology, Inc | Multiple bit line column redundancy |
| CA2434643C (en) * | 2001-01-18 | 2013-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of.delta.pkc |
-
2003
- 2003-04-22 WO PCT/US2003/012541 patent/WO2003089456A2/en not_active Ceased
- 2003-04-22 US US10/421,503 patent/US7507711B2/en not_active Expired - Fee Related
- 2003-04-22 US US10/513,003 patent/US7393835B2/en not_active Expired - Fee Related
- 2003-04-22 EP EP10178878A patent/EP2332559A1/en not_active Withdrawn
- 2003-04-22 CA CA2481512A patent/CA2481512C/en not_active Expired - Fee Related
- 2003-04-22 CA CA2785889A patent/CA2785889A1/en not_active Abandoned
- 2003-04-22 EP EP03728495A patent/EP1501533A4/en not_active Withdrawn
- 2003-04-22 CA CA2482598A patent/CA2482598C/en not_active Expired - Fee Related
- 2003-04-22 US US10/421,548 patent/US7459424B2/en not_active Expired - Fee Related
- 2003-04-22 WO PCT/US2003/012542 patent/WO2003089457A2/en not_active Ceased
- 2003-04-22 AU AU2003234186A patent/AU2003234186B2/en not_active Ceased
- 2003-04-22 EP EP03728494A patent/EP1501532A4/en not_active Withdrawn
- 2003-04-22 JP JP2003586177A patent/JP2005527209A/ja active Pending
- 2003-04-22 JP JP2003586176A patent/JP2005523326A/ja not_active Withdrawn
- 2003-04-22 AU AU2003234185A patent/AU2003234185C1/en not_active Ceased
-
2007
- 2007-07-16 US US11/879,414 patent/US7833984B2/en not_active Expired - Fee Related
-
2008
- 2008-06-16 US US12/214,104 patent/US7939493B2/en not_active Expired - Fee Related
- 2008-08-27 US US12/229,992 patent/US20090143293A1/en not_active Abandoned
-
2009
- 2009-01-20 JP JP2009010402A patent/JP2009091372A/ja active Pending
- 2009-01-21 JP JP2009011456A patent/JP2009102392A/ja active Pending
- 2009-04-22 AU AU2009201593A patent/AU2009201593B2/en not_active Ceased
- 2009-05-04 AU AU2009201760A patent/AU2009201760B2/en not_active Ceased
-
2011
- 2011-05-05 US US13/101,540 patent/US8658594B2/en not_active Expired - Fee Related
-
2012
- 2012-06-06 JP JP2012128849A patent/JP2012176978A/ja active Pending
-
2014
- 2014-02-21 US US14/187,070 patent/US9365837B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000004914A1 (en) * | 1998-07-21 | 2000-02-03 | Cytovia, Inc. | Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof |
| JP2005523326A (ja) * | 2002-04-22 | 2005-08-04 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | プロテインキナーゼｃのペプチドインヒビター |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006525948A (ja) * | 2003-05-16 | 2006-11-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 離脱症状における使用のためのプロテインキナーゼｃペプチド |
| JP2010516709A (ja) * | 2007-01-19 | 2010-05-20 | カイ ファーマシューティカルズ インコーポレーティッド | 疼痛減弱のためのイプシロン阻害化合物の使用方法 |
| JP2010516707A (ja) * | 2007-01-19 | 2010-05-20 | カイ ファーマシューティカルズ インコーポレーティッド | ペプチド組成物の安定性および送達効率を上昇させるための修飾方法 |
| JP2014224126A (ja) * | 2007-01-19 | 2014-12-04 | カイ ファーマシューティカルズ インコーポレーティッド | ペプチド組成物の安定性および送達効率を上昇させるための修飾方法 |
| KR101775929B1 (ko) * | 2007-01-19 | 2017-09-07 | 카이 파마슈티컬즈 | 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 |
| JP2018111717A (ja) * | 2007-01-19 | 2018-07-19 | カイ ファーマシューティカルズ インコーポレーティッド | ペプチド組成物の安定性および送達効率を上昇させるための修飾方法 |
| KR20190140111A (ko) * | 2007-01-19 | 2019-12-18 | 카이 파마슈티컬즈 | 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 |
| JP2021098725A (ja) * | 2007-01-19 | 2021-07-01 | カイ ファーマシューティカルズ インコーポレーティッド | ペプチド組成物の安定性および送達効率を上昇させるための修飾方法 |
| KR102274003B1 (ko) | 2007-01-19 | 2021-07-08 | 카이 파마슈티컬즈 | 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 |
| JP2023078424A (ja) * | 2007-01-19 | 2023-06-06 | カイ ファーマシューティカルズ インコーポレーティッド | ペプチド組成物の安定性および送達効率を上昇させるための修飾方法 |
| JP2010523598A (ja) * | 2007-04-06 | 2010-07-15 | カイ・ファーマシューティカルズ・インコーポレイテッド | 痛みの軽減のためのガンマ阻害剤化合物の使用方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7459424B2 (en) | Peptide inhibitors of protein kinase C γ for pain management | |
| Li et al. | BDNF contributes to spinal long-term potentiation and mechanical hypersensitivity via Fyn-mediated phosphorylation of NMDA receptor GluN2B subunit at tyrosine 1472 in rats following spinal nerve ligation | |
| JP2020526554A (ja) | 疼痛を管理するための方法 | |
| Harward et al. | BDNF/TrkB signaling and epileptogenesis | |
| AU2012216402A1 (en) | Peptide inhibitors of protein kinase Cy for pain management | |
| CN101873865A (zh) | 编码破伤风毒素重链羧基端结构域的序列作为药物的用途 | |
| de Moraes et al. | Temporal regulation of TRP channels during partial sciatic nerve ligation is modulated by PLCγ in male mice | |
| JP4675109B2 (ja) | 離脱症状における使用のためのプロテインキナーゼｃペプチド | |
| AU2011202912A1 (en) | Peptide inhibitors of protein kinase C | |
| WO2011021221A2 (en) | Compositions for spinal cord injury | |
| JP2010090176A (ja) | 離脱症状における使用のためのプロテインキナーゼｃペプチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060328 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20081020 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090120 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090511 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100423 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100722 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100729 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100820 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100827 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100922 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101018 |